International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Roflumilast – A Potential New First Line Systemic Drug for Psoriasis

Roflumilast – A Potential New First Line Systemic Drug for Psoriasis

Claus Zachariae, MD, DMSci | Denmark
2022

Featured Experts